Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
Phil Waters, Tina Broder – 14 December 2018
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Syed‐Mohammed Jafri, Stuart C. Gordon – 14 December 2018
Tram T. Tran – 14 December 2018
Xiaoying Liu, Richard M. Green – 14 December 2018
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
Dongshi Chen, Hong‐Min Ni, Lei Wang, Xiaowen Ma, Jian Yu, Wen‐Xing Ding, Lin Zhang – 14 December 2018 – Acetaminophen (APAP) overdose is one of the leading causes of hepatotoxicity and acute liver failure in the United States. Accumulating evidence suggests that hepatocyte necrosis plays a critical role in APAP‐induced liver injury (AILI). However, the mechanisms of APAP‐induced necrosis and liver injury are not fully understood.
Ruben Khan, Sugir Velpari, Sean Koppe – 14 December 2018
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Carmen Unzu, Evarist Planet, Nathalie Brandenberg, Floriane Fusil, Marco Cassano, Jimena Perez‐Vargas, Marc Friedli, François‐Loïc Cosset, Matthias P. Lutolf, Barbara E. Wildhaber, Didier Trono – 14 December 2018 – The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential in vitro, a major limitation for the cell‐based therapy of liver disorders and for ex vivo biological screens.